News | 13 June 2023
Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData
Pfizer is likely to show GSK significant competition
Pfizer is likely to show GSK significant competition
The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
UTD2 is the world's first oral epothilone microtubule inhibitor
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Under the terms of the VPPA, IGNIS will produce renewable energy equal to Lonza’s electricity needs across Switzerland and the European Union.
Construction will begin this year with the new capacity anticipated by 2025
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
The new recycling facility, Recover Louth, is the second addition to Coveris’ closed loop recycling business segment
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
The collaboration focuses on the development and sharing of Standard Quality and Regulatory Documentation (StaQRD), a standard guide for the electronic transfer of information
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
Subscribe To Our Newsletter & Stay Updated
